Treatment of Alcohol Withdrawal in Hospital Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.

Clinical Trial Description

Studies show that symptom-triggered dosing is best for treatment of alcohol withdrawal in patients on chemical dependence units without other illness. On general medical hospital wards, withdrawal may be affected by comorbid medical illness. A clinical trial was undertaken to determine whether there is a difference between symptom-triggered (ST) and fixed-schedule (FS) dosing of lorazepam in patients hospitalized on general medical wards at a University medical center. Subjects were assessed by their nurses with the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale. Subjects in the ST arm received lorazepam doses based on CIWA-Ar score. Subjects in the FS arm received scheduled lorazepam with tapering over 4 days. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00249366
Study type	Interventional
Source	Virginia Commonwealth University
Contact
Status	Completed
Phase	Phase 4
Start date	April 2001
Completion date	May 2003

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03033823` - MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)	Phase 3
Completed	`NCT02146716` - Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.	N/A
Completed	`NCT01637415` - The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS)	N/A
Completed	`NCT04973202` - Portrayal of Hospital Alcohol Detoxification in France
Terminated	`NCT02052440` - Preventing Alcohol Withdrawal Syndrome With Oral Baclofen	Phase 3
Completed	`NCT01652326` - Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome	N/A
Recruiting	`NCT03235531` - Assessment of Valproate on Ethanol Withdrawal	Phase 4
Completed	`NCT00146471` - Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome	Phase 3
Completed	`NCT02090504` - Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome	Phase 4
Completed	`NCT03012815` - Gabapentin for Alcohol Withdrawal Syndrome	Phase 4
Completed	`NCT05438641` - Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Withdrawn	`NCT03788889` - Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine	Phase 4